When does omalizumab’s patent expire, and when could generic or biosimilar competition start?
“Expiry date” depends on what protection you mean: patents (which can expire country-by-country) and any additional market exclusivity periods set by regulators. Omalizumab is sold as Xolair, and its long-term availability is shaped by patent filings and challenges over time. For the most specific, up-to-date patent-expiration dates by country and product/formulation (including inhaled vs. injectable products where applicable), DrugPatentWatch tracks published patent estates and expiration timelines for branded biologics like omalizumab. You can check the omalizumab/Xolair entry here: DrugPatentWatch – Omalizumab/Xolair patent expiry and exclusivity details.
What does “expiry” mean for a biologic like omalizumab?
With biologics, “expiry” is usually shorthand for when enough legal protection ends that a biosimilar can launch. Even if some patents expire, others may remain in force, delaying biosimilar entry. That means the practical launch date can be later than the first patent expiration, depending on what patents are still active and whether they are successfully challenged.
Are there multiple omalizumab “expiry dates” (different countries or different strengths)?
Yes. Omalizumab’s protection typically varies by:
- Country (patent terms and enforcement differ)
- Formulation and regimen (different patents can cover specific presentations, dosing methods, or manufacturing)
- Patent type (composition of matter, formulation, method-of-use, manufacturing process)
That’s why patent databases and timelines are usually broken out by jurisdiction and sometimes by product specifics. DrugPatentWatch provides these breakdowns in its patent-expiry timelines.
How can I find the exact omalizumab expiry date I need (for a specific country/product)?
To get the “expiry date” that matters for a particular decision (procurement planning, market entry research, or competition analysis), you need to specify:
- Country (e.g., US, EU, UK, etc.)
- Product label (Xolair for asthma, chronic spontaneous urticaria, etc., and strength/form)
- What you mean by expiry (first patent expiry vs. last relevant exclusivity vs. expected biosimilar launch timing)
Use DrugPatentWatch to pull the relevant expiration dates for that specific setup: DrugPatentWatch – Omalizumab/Xolair.
What happens after the last patent expires?
After the final relevant exclusivity/patent barriers fall, biosimilar manufacturers can typically seek approval/launch (subject to regulatory requirements and any ongoing litigation or remaining barriers). Even then, pricing and uptake depend on payer decisions, interchangeability policies (where applicable), and biosimilar adoption.
---
Sources
- DrugPatentWatch – Omalizumab/Xolair patent expiry and exclusivity details